On Monday, May 16th, 2011, Dr. Andrew Kennedy, a well-known researcher in liver metastases, led a Fight Colorectal Cancer webinar discussing an issue that affects thousands of colorectal cancer patients.

Colorectal cancer often metastasizes first to the liver, so learning how to manage growth of those tumors can help with patient survival.  

Treatment of liver mets has come a long way in the last two decades. You can learn about these developments in an archive of the webinar below.

Our thanks to Dr. Andrew Kennedy for leading the discussion. His extensive knowledge of this issue is highly respected in the field of radiology. He graciously donated his time to bring this information to patients.

Webinar: Treating Liver Metastases from Fight Colorectal Cancer on Vimeo.

Fight Colorectal Cancer is giving you the opportunity to talk to researchers and medical professionals in April and May through online webinars designed to bring the science of treating colorectal cancer down to the personal.

The latest news from the petri dish
Wednesday, April 20, 2011
8 – 9 PM Eastern

Dr. Yaeger at work in her lab

Dr. Rona Yaeger will discuss the research she has been conducting over the past year with the grant she received as part of Fight Colorectal Cancer’s Lisa Fund research program.

Dr. Yaeger’s research focused on inhibiting the AKT pathway in colorectal cancer cells. She conducted basic research to determine how inhibitors to the pathway might affect cells of patients who have mutated KRAS and are resistant to EGFR inhibiting drugs. Dr. Yaeger has also been conducting a phase II clinical trial with an AKT inhibitor for patients with metastatic colorectal cancer who have normal (wild type) KRAS.

If you are interested in learning more about the future of cancer treatments, or if you’ve ever donated to the Fight Colorectal Cancer Lisa Fund, do not miss this webinar!

Read the rest of this entry »

dendritic immune cell

Doctors at Dartmouth-Hitchcock Medical Center in New Hampshire have built personalized cancer vaccines that use the patient’s own immune system to fight colorectal cancer.

The key to success was first removing bulky liver tumors and then using the vaccine to kill any tiny cancers remaining in the body.

Five years after getting the vaccine, two-thirds of patients whose systems produced an immune response to the vaccine were alive and cancer free. Read the rest of this entry »